{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"25.8","value":"15.8"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"11.9","value":"8.2"},{"comment":"range 0.49-24 months. 95% CI not estimable","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Overall survival (months) defined as the time from the date of first infusion of Tagraxofusp to the date of death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"First-line BPDCN patients enrolled across stages","id":"OG000","title":"First-line BPDCN"},{"description":"R/R BPDCN patients enrolled across stages","id":"OG001","title":"R/R BPDCN"},{"description":"AML patients enrolled in stages 1 and 2","id":"OG002","title":"Acute Myeloid Leukemia"}],"paramType":"MEDIAN","populationDescription":"Efficacy population including evaluable patients treated at 12 μg/kg/day in the first-line BPDCN, R/R BPDCN and AML","reportingStatus":"POSTED","timeFrame":"From first infusion to treatment discontinuation when survival is assessed every 90 days up to end of follow-up or death, up to 5 years","title":"OS in First-line BPDCN, R/R BPDCN and AML","type":"SECONDARY","unitOfMeasure":"Months"}